RE:280 mill annualized cashflow vs $3.5 Billion debtDrunkmoon: no problem at all since the debt and high interest is the norm in the generic drug business. The market put it in the spot light as of late but that's just how all these companies do business, as long as there is no accounting scandals, and the markets reward that model as its a recession proof cash cow. The debt was at its highest back when Goldman Sachs bought most of the share issuance at $65 usd. Are you saying that Goldman badly invested their money ? The market sentiment and the cloud over the whole sector will dissipate very soon and Cxr will trade at the right multiple assuming it's still listed and not bought out by a private firm. With all the respect I suggest that you educate yourself about the business model Cxr falls under. This is not a double from here, its a triple. Wait until there is a rush to the door by the shorts, 9 million in a 52 million float mostly tightly held by institutions. That alone will more than double the price. If thus creeps up to the high forties it will 100% be taken out.